New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition
Open label study demonstrated statistically significant effects of early treatment with rivipansel on time to discharge and time to discontinuation of intravenous opioids
Benefit of early intervention with E-selectin antagonist in acute VOC now reproduced in independent, contemporaneous dataset that includes both the all-ages and pediatric populations
Company expects to initiate Investigational New Drug-enabling work with GMI-1687 during 2021
In his oral presentation,
Dr. Wun’s presentation highlighted data from the OLE trial reproducing the RESET efficacy outcomes for patients treated early with rivipansel. For the all-ages study population:
|
|
The OLE study results, presented for the first time at ASH, began in December of 2015 and treated 81 patients ages six years or older who had completed the double-blind Phase 3 RESET study. The study was designed to evaluate the safety of rivipansel as a treatment for one or more VOC events in hospitalized subjects with SCD. In this context, the OLE protocol originally included collection of data for TTD and TTDIVO analyses as part of the safety assessment. Upon completion of the post hoc analysis of the RESET trial dataset,
In addition to the rivipansel data,
The presentation will be available on the Company’s website at www.glycomimetics.com under
Title: Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis (abstract #678)
Presenter:
Session
Date and Time:
Presentation Time:
About Rivipansel
Rivipansel, the Company’s wholly-owned glycomimetic drug candidate that binds to all three members of the selectin family (E-, P- and L-selectin), was GlycoMimetics’ first drug candidate to enter clinical development. After the Phase 3 RESET trial conducted by Pfizer, GlycoMimetics’ former collaborator, did not meet its primary or key secondary efficacy endpoints in 2019, new efficacy data from a post hoc analysis of rivipansel were published in
About GMI-1687
Discovered and developed by
About
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include those relating to the planned or potential clinical development of the Company’s product candidates, including the Company’s engagement with regulatory authorities, as well as the presentation of data from preclinical studies and clinical trials and the potential benefits and impact of the Company’s drug candidates. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing
View source version on businesswire.com: https://www.businesswire.com/news/home/20201207005791/en/
Investor Contact:
Phone: 650-888-0902
Email: sannes@annesassociates.com
Media Contact:
Phone: 410-299-3310
Email: jamielacey@presscommpr.com
Source: